Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Hello, please describe your problem in detail, then only we'll be able to provide you treatment costs. You can call us on +91-8010994994 and talk to our medical expert.
In general, yes it is safe. But there are exceptions based on the conditions. A woman who is developing breast cancer might be excreting small amounts of fluids from the nipples. A woman who is lactating (to feed babies) is also ‘leaking’ fluids. Now, whenever a fluid is exchanged between two bod....
Don’t worry, most breast cysts can be very small and will only show up on ultrasound scans, and these are termed microcysts. About 25% of breast cysts enlarge gradually into ‘big-enough’ cysts to become a palpable breast lump. Breast cysts are extremely common, and occur in as many as one third of ....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
लिहिलेले:Dr. Nitika Sharma - BDS
पुनरावलोकन:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.